The $122.5M upfront provides near-term cash runway extension without dilution, but the sale of manufacturing capabilities signals a shift to a more asset-light model. Monitor Q3 2026 closing and any pipeline updates (e.g., lorigerlimab data) that could drive re-rating.
MGNX drugs
MGNX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $3.52entry
- T+1 · 6mo ago 0.00%α −0.54% · $3.52
- T+5 · 6mo ago +23.58%α +23.50% · $4.35
- T+20 · 5mo ago +9.94%α +11.67% · $3.87
- T+60 · 3mo ago +13.92%α +9.54% · $4.01
Price Chart
How similar events traded
Executive Summary
MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment. The deal transfers the Rockville, MD facility (11,000L capacity), Frederick warehouse, and ~140 employees to Bora, while MacroGenics retains a supply arrangement for its pipeline needs. This non-dilutive capital infusion supports the company's pipeline advancement but reflects a strategic pivot away from internal manufacturing.
Key Financial Metrics
Key Facts
- Upfront payment of $122.5 million from Bora Pharmaceuticals upon closing.
- Transfer of Rockville, MD manufacturing site (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
- MacroGenics will have a supply arrangement with Bora for process development and drug substance production.
- Transaction expected to close in Q3 2026.
- Moelis & Company and Sidley Austin advised MacroGenics; Jones Day advised Bora.
Financial Impact
$122.5 million upfront payment, non-dilutive capital for pipeline funding.
Risk Factors
- Closing conditions may delay or prevent transaction completion.
- Loss of internal manufacturing control could increase dependency on Bora for supply.
- Pipeline setbacks (e.g., clinical trial failures) could erode the value of the capital infusion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292410 |
Track record
21 reports on MGNX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
- Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers